Evidence map›Paper›PMID 27745822›Full record

ArticleThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2017

Cognition and Dopamine D

Tarek K Rajji, Benoit H Mulsant, Shinichiro Nakajima, Fernando Caravaggio, Takefumi Suzuki, Hiroyuki Uchida, Philip Gerretsen, Wanna Mar, Bruce G Pollock, David C Mamo and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. High long-term test-retest reliability for extrastriatalJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Article
  4. The role of striatal dopamine DPsychopharmacology · 2018
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Tarek K RajjiGeriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: Tarek.Rajji@camh.ca.
Benoit H MulsantGeriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Shinichiro NakajimaGeriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Multimodal Imaging Group-Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Fernando CaravaggioCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Multimodal Imaging Group-Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Takefumi SuzukiDepartment of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Hiroyuki UchidaGeriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan.
Philip GerretsenGeriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Multimodal Imaging Group-Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Wanna MarMultimodal Imaging Group-Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Bruce G PollockGeriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
David C MamoDepartment of Psychiatry, Faculties of Medicine and Health Science, University of Malta, Msida, Malta.
Ariel Graff-GuerreroGeriatric Psychiatry Division, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Multimodal Imaging Group-Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Centre for Addiction and Mental Health · CAKeio University · JPUniversity of Toronto · CAUniversity of Malta · MT

Funding

Optimal Dosing of Antipsychotic Drugs in Late LifeR01MH084886 · NIMH · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI MAMO, DAVID · 2010 to 2014
$761k
CIHR MOP-9794NIMH NIH HHS R01 MH084886
6 · The paper itself

Abstract

objectivesTo assess the impact of reducing the dose of antipsychotics on cognition and dopaminergic D

designOpen-label prospective PET [

settingA tertiary care center outpatient setting.

participantsThirty-seven clinically stable participants with schizophrenia or schizoaffective disorder, aged 50 years or greater, and having been treated with olanzapine or risperidone monotherapy at the same dose for at least 6 months.

interventionGradual reduction in their olanzapine or risperidone daily dose of up to 40%. MEASUREMENTS: Clinical and cognitive assessments, and [

resultsReducing the antipsychotic dose resulted in an increase in D

conclusionsOur findings suggest that optimizing D

Indexed as

Psychotic DisordersAgedAntipsychotic AgentsBenzodiazepinesCognitive DysfunctionCorpus StriatumFemaleHumansMaleMiddle AgedOlanzapinePositron-Emission TomographyRacloprideReceptors, Dopamine D2RisperidoneSchizophreniaAntipsychotic AgentsBenzodiazepinesDRD2 protein, humanOlanzapineRacloprideReceptors, Dopamine D2RisperidoneantipsychoticcognitionD(2) receptorlate-life schizophreniaPET

Identifiers

PMID27745822
PMCPMC5164861
OpenAlexW2489904471

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.